Shield Therapeutics (LON:STX) Announces Earnings Results

Shield Therapeutics (LON:STX) announced its quarterly earnings results on Thursday. The company reported GBX (3) (($0.04)) EPS for the quarter, Digital Look Earnings reports. Shield Therapeutics had a negative net margin of 173.43% and a negative return on equity of 470.50%.

Shield Therapeutics Stock Performance

LON:STX opened at GBX 2.39 ($0.03) on Friday. Shield Therapeutics has a twelve month low of GBX 1.20 ($0.02) and a twelve month high of GBX 5.87 ($0.08). The stock has a market cap of £23.58 million, a P/E ratio of -0.62 and a beta of 1.42. The business’s 50-day moving average price is GBX 2.96 and its two-hundred day moving average price is GBX 3.02. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50.

Insider Activity

In other news, insider Anders Lundstrom purchased 575,000 shares of Shield Therapeutics stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of GBX 4 ($0.05) per share, with a total value of £23,000 ($30,625.83). Corporate insiders own 62.16% of the company’s stock.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.